Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Schedule an appointment today
Call to Schedule: 1-866-UH4-CARE
Nuclear Radiology Fellowship
Visit the Research & Education Institute

Education & Technology

The Nuclear Medicine Division is committed to excellence in imaged-based clinical care. Our health system comprises over 15 hospitals and the majority of all nuclear medicine studies are interpreted at University Hospitals Cleveland Medical Center. We provide a full spectrum of diagnostic imaging with state-of-the-art equipment, including five PET/CT scanners, digital PET/CT and PET/MR.

Additionally, we are equipped with the latest Discovery NM/CT 870 DR and the 670 CZT digital SPECT/CT system. We offer comprehensive radionuclide diagnostic procedures and therapies including:

  • I-131
  • Lu-177 Dotatate
  • Ra-223 Xofigo
  • Y-90 microspheres
  • Y-90 Zevalin

We utilize a variety of advanced software tools for diagnostic work, including:

Comprehensive Training in Nuclear Medicine

The fellowship program includes training in general nuclear medicine, pediatric nuclear medicine with UH Rainbow Babies & Children's, nuclear cardiology with UH Harrington Heart & Vascular Institute and positron emission tomography (PET) with UH Seidman Cancer Center. It also teaches the safe handling and use of unsealed radioactive drugs for medical purposes, which involves quality control and quality assurance training.

There are weekly conferences covering all aspects of nuclear medicine as well as weekly journal clubs and seminars. Trainee responsibilities increase progressively throughout the year, from close supervision during the first six months of training to greater independent responsibility later on.

Research Opportunities

Our staff are all active in research and clinical innovation in the following medical organizations:

Our division has access to a cyclotron and is operating a new human use PET radiopharmacy for the development of new molecular imaging agents. There are plenty of research opportunities in the use of experimental PET radiopharmaceuticals together with either PET/CT or PET/MR. We currently have an Investigational New Drug (IND) clearance from the FDA for F-18 fluorothymidine (FLT) and Ga-68 PSMA to explore early cancer therapy response assessment.